Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors.
暂无分享,去创建一个
K. Nørsett | B. Hoff | E. Sundby | S. Henriksen | J. Han
[1] K. Nørsett,et al. Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors. , 2016, European journal of medicinal chemistry.
[2] L. Olsen,et al. Enthalpy-Entropy Compensation in the Binding of Modulators at Ionotropic Glutamate Receptor GluA2. , 2016, Biophysical journal.
[3] B. Hoff,et al. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[4] B. Hoff,et al. Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. , 2015, European journal of medicinal chemistry.
[5] Y. Yosaatmadja,et al. 1.85 angstrom structure of EGFR kinase domain with gefitinib , 2014 .
[6] H. Kim,et al. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer , 2014, British Journal of Cancer.
[7] Xingrong Liu,et al. Rational use of plasma protein and tissue binding data in drug design. , 2014, Journal of medicinal chemistry.
[8] G. Bjørkøy,et al. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[9] M. Moore,et al. Assessing the role of the EGF receptor in the development and progression of pancreatic cancer , 2014 .
[10] U. Nonstad,et al. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. , 2014, European journal of medicinal chemistry.
[11] J. Rubio-Martínez,et al. Microwave‐Assisted Synthesis of Substituted Pyrrolo[2,3‐d]pyrimidines , 2014 .
[12] Z. O’Brien,et al. Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data , 2013, Expert opinion on drug metabolism & toxicology.
[13] W. Pao,et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.
[14] E. Sausville,et al. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2 , 2013, Investigational New Drugs.
[15] Daisuke Kitagawa,et al. Activity‐based kinase profiling of approved tyrosine kinase inhibitors , 2013, Genes to cells : devoted to molecular & cellular mechanisms.
[16] A. Ardizzoni,et al. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines , 2012, Molecular Cancer.
[17] Thomas J. Raub,et al. How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.
[18] Toshimasa Tanaka,et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. , 2012, Bioorganic & medicinal chemistry.
[19] Hongjian Xu,et al. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. , 2012, European journal of medicinal chemistry.
[20] C. Fotsch,et al. Mitigating heterocycle metabolism in drug discovery. , 2012, Journal of medicinal chemistry.
[21] K. Linton,et al. Investigational ABC transporter inhibitors , 2012, Expert opinion on investigational drugs.
[22] A. Ohtsu,et al. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients , 2012, British Journal of Cancer.
[23] G. Bjørkøy,et al. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines. , 2011, European journal of medicinal chemistry.
[24] Masashi Honma,et al. Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders , 2011, Molecular Pharmacology.
[25] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[26] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[27] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[28] P. Marathe,et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. , 2010, Journal of pharmaceutical sciences.
[29] M. Hewitt,et al. The kinetic isotope effect in the search for deuterated drugs. , 2010, Drug news & perspectives.
[30] G. Mills,et al. Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.
[31] Vijay T. Ahuja,et al. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. , 2009, Journal of medicinal chemistry.
[32] M. Watson,et al. Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines , 2008, Journal of Nuclear Medicine.
[33] S. Buchwald,et al. An improved system for the palladium-catalyzed borylation of aryl halides with pinacol borane. , 2008, The Journal of organic chemistry.
[34] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[35] P. Graczyk. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. , 2007, Journal of medicinal chemistry.
[36] M. Verdonk,et al. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.
[37] Joelle M. R. Gola,et al. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery , 2006, Expert opinion on drug metabolism & toxicology.
[38] C. Prakash,et al. METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.
[39] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[40] Woody Sherman,et al. Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.
[41] C. Laggner,et al. Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.
[42] C. Bucana,et al. AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice , 2005, Clinical Cancer Research.
[43] L. Bubendorf,et al. Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.
[44] John N Weinstein,et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.
[45] J. Mestan,et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.
[46] P. Traxler. Tyrosine kinases as targets in cancer therapy – successes and failures , 2003, Expert opinion on therapeutic targets.
[47] Arun K Mandagere,et al. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. , 2002, Journal of medicinal chemistry.
[48] M. Birrer,et al. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. , 1997, Cancer research.
[49] J D Dunitz,et al. Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. , 1995, Chemistry & biology.
[50] K. Münger,et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[51] B. Ozanne,et al. Human squamous cell lung cancers express increased epidermal growth factor receptors. , 1984, The Journal of clinical investigation.
[52] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.